Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia.

Elena InzoliElena CrisàNovella PuglieseIvan CivettiniGiuseppe LanzaroneAndrea CastelliVincenzo MartinelliLaura MonteliscianiLaura AntoliniCarlo Gambacorti-PasseriniElena Maria Elli

Published in: European journal of haematology (2022)

B-ESA seems to be an effective and well-tolerated option for anemia treatment in the MF setting. This strategy deserves further clinical investigation. This article is protected by copyright. All rights reserved.

Keyphrases

chronic kidney disease
iron deficiency
combination therapy
replacement therapy